Oncolytic viruses (OVs) are appealing anti-tumor agents. But it is limited in its effectiveness. In this study, we used combination therapy with immune checkpoint inhibitor to enhance the antitumor efficacy of OVs. Using reverse genetics technology, we rescued an oncolytic influenza virus with the name delNS1-GM-CSF from the virus. After identifying the hemagglutination and 50% tissue culture infectivedose (TCID50) of delNS1-GM-CSF, it was purified, and the viral morphology was observed under electron microscopy. Reverse transcription quantitative-polymerase chain reaction (RT-qPCR) was used to identify the level of GM-CSF expression in delNS1-GM-CSF, and the GM-CSF expression level was determined after infection with delNS1-GM-CSF by enzyme linked immunosorbent assay (ELISA). To study the tumor-killing effect of delNS1-GM-CSF, we utilized the hepatocellular carcinoma (HCC) tumor-bearing mouse model. To examine signaling pathways, we performed transcriptome sequencing on mouse tumor tissue and applied western blotting to confirm the results. Changes in T-cell infiltration in HCC tumors following treatment were analyzed using flow cytometry and immunohistochemistry. DelNS1-GM-CSF can target and kill HCCs without damaging normal hepatocytes. DelNS1-GM-CSF combined with programmed cell death 1 blockade therapy enhanced anti-tumor effects and significantly improved mouse survival. Further, we found that combination therapy had an antitumor impact via the janus kinase-signal transducer and activator of transcription (JAK2-STAT3) pathway as well as activated CD4+ and CD8+T cells. Interestingly, combined therapy also showed promising efficacy in distant tumors. DelNS1-GM-CSF is well targeted. Mechanistic investigation revealed that it functions through the JAK2-STAT3 pathway. Combination immunotherapies expected to be a novel strategy for HCC immunotherapy.
Get full access to this article
View all access options for this article.
References
1.
SungH, FerlayJ, SiegelRL, et al.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71:209–249.
2.
VogelA, MeyerT, SapisochinG, et al.Hepatocellular carcinoma. Lancet, 2022; 400:1345–1362.
3.
SiegelRL, MillerKD, JemalA. Cancer statistics, 2019. CA Cancer J Clin, 2019; 69:7–34.
MarreroJA, KulikLM, SirlinCB, et al.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018; 68:723–750.
6.
WangJH, ChangchienCS, HuTH, et al.The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma—Survival analysis of 3892 patients. Eur J Cancer, 2008; 44:1000–1006.
7.
LlovetJM, MontalR, SiaD, et al.Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol, 2018; 15:599–616.
8.
ChengAL, KangYK, ChenZ, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009; 10:25–34.
9.
QinS, BiF, GuS, et al.Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol, 2021; 39:3002–3011.
10.
SchreiberRD, OldLJ, SmythMJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science, 2011; 331:1565–1570.
11.
ZhangY, ZhangZ. The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol, 2020; 17:807–821.
12.
CammarotaA, ZanusoV, ManfrediGF, et al.Immunotherapy in hepatocellular carcinoma: How will it reshape treatment sequencing?. Ther Adv Med Oncol, 2023; 15:7407235.
13.
QinS, FinnRS, KudoM, et al.RATIONALE 301 study: Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol, 2019; 15:1811–1822.
14.
YauT, ParkJW, FinnRS, et al.Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol, 2022; 23:77–90.
15.
FinnRS, RyooBY, MerleP, et al.Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol, 2020; 38:193–202.
16.
HerbstRS, SoriaJC, KowanetzM, et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014; 515:563–567.
17.
PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012; 12:252–264.
18.
RibasA. Adaptive immune resistance: How cancer protects from immune attack. Cancer Discov, 2015; 5:915–919.
19.
BluestoneJA, AndersonM. Tolerance in the age of immunotherapy. N Engl J Med, 2020; 383:1156–1166.
20.
RuizDGM, BresnahanE, Molina-SanchezP, et al.Beta-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov, 2019; 9:1124–1141.
21.
ZhouJ, LiuM, SunH, et al.Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut, 2018; 67:931–944.
22.
FinnRS, QinS, IkedaM, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med, 2020; 382:1894–1905.
23.
SamsonA, BenthamMJ, ScottK, et al.Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut, 2018; 67:562–573.
24.
NakatakeR, KaiboriM, NakamuraY, et al.Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice. Cancer Sci, 2018; 109:600–610.
LeberMF, NeaultS, JirovecE, et al.Engineering and combining oncolytic measles virus for cancer therapy. Cytokine Growth Factor Rev, 2020; 56:39–48.
29.
KaufmanHL, KohlhappFJ, ZlozaA. Oncolytic viruses: A new class of immunotherapy drugs. Nat Rev Drug Discov, 2015; 14:642–662.
30.
LawlerSE, SperanzaMC, ChoCF, et al.Oncolytic viruses in cancer treatment: A review. JAMA Oncol, 2017; 3:841–849.
31.
MondalM, GuoJ, HeP, et al.Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother, 2020; 16:2389–2402.
32.
TrusE, BastaS, GeeK. Who's in charge here? Macrophage colony stimulating factor and granulocyte macrophage colony stimulating factor: Competing factors in macrophage polarization. Cytokine, 2020; 127:154939.
33.
KuznetsovaI, ArnoldT, AschacherT, et al.Targeting an oncolytic influenza A virus to tumor tissue by elastase. Mol Ther Oncolytics, 2017; 7:37–44.
34.
WanPK, RyanAJ, SeymourLW. Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Mol Ther, 2021; 29:1668–1682.
35.
PenghuiY, FangS, RuilanW, et al.Oncolytic activity of a novel influenza A virus carrying granulocyte-macrophage colony-stimulating factor in hepatocellular carcinoma. Hum Gene Ther, 2019; 30:330–338.
36.
MachN, GillessenS, WilsonSB, et al.Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res, 2000; 60:3239–3246.
37.
BrozML, BinnewiesM, BoldajipourB, et al.Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell, 2014; 26:638–652.
38.
HercusTR, ThomasD, GuthridgeMA, et al.The granulocyte-macrophage colony-stimulating factor receptor: Linking its structure to cell signaling and its role in disease. Blood, 2009; 114:1289–1298.
39.
DranoffG, JaffeeE, LazenbyA, et al.Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A, 1993; 90:3539–3543.
40.
HoellerC, JansenB, Heere-RessE, et al.Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases. J Invest Dermatol, 2001; 117:371–374.
41.
KaufmanHL, RubyCE, HughesT, et al.Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer, 2014; 2:11.
42.
LiuBL, RobinsonM, HanZQ, et al.ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther, 2003; 10:292–303.
43.
AndtbackaRH, KaufmanHL, CollichioF, et al.Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol, 2015; 33:2780–2788.
ShiX, ZhangX, LiJ, et al.PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine. Int J Cancer, 2018; 142:2106–2117.
46.
XuD, ZhaoM, SongY, et al.Novel insights in preventing Gram-negative bacterial infection in cirrhotic patients: Review on the effects of GM-CSF in maintaining homeostasis of the immune system. Hepatol Int, 2015; 9:28–34.
47.
HoMY, SunGH, LeuSJ, et al.Combination of Fasl and GM-CSF confers synergistic antitumor immunity in an in vivo model of the murine Lewis lung carcinoma. Int J Cancer, 2008; 123:123–133.
48.
OhDY, FongL, NewellEW, et al.Toward a better understanding of T cells in cancer. Cancer Cell, 2021; 39:1549–1552.
49.
SaxenaNK, SharmaD, DingX, et al.Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res, 2007; 67:2497–2507.
50.
IrikiT, OhnishiK, FujiwaraY, et al.The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation. Lung Cancer, 2017; 106:22–32.
51.
LejeuneD, DumoutierL, ConstantinescuS, et al.Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem, 2002; 277:33676–33682.
52.
KortylewskiM, KujawskiM, WangT, et al.Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med, 2005; 11:1314–1321.
53.
IorioR, FrisulloG, NocitiV, et al.T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. Clin Immunol, 2009; 131:70–83.
54.
ZhangC, YueC, HerrmannA, et al.STAT3 Activation-induced fatty acid oxidation in CD8(+) T effector cells is critical for obesity-promoted breast tumor growth. Cell Metab, 2020; 31:148–161.
55.
SongTL, NairismagiML, LaurensiaY, et al.Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood, 2018; 132:1146–1158.
56.
ShenM, XuZ, XuW, et al.Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J Exp Clin Cancer Res, 2019; 38:149.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
